April 30, 2020 – Today
Insilico Medicine
has announced that
Frost & Sullivan
named it as a top innovator in drug discovery, highlighting it as a technology pioneer in this industry.
Generative AI is an emerging technology in both chemistry and biology. Insilico Medicine has been working in these areas since 2015, and holds the critical intellectual property in generative biology for generation of synthetic biological data, target discovery, and cross-tissue and cross-species analysis; generative chemistry for generation of novel molecules, and generative medicine for prediction of clinical trials outcomes. According to recent legal opinions, drugs generated using
AI may be classified as being invented by AI
. Insilico published its
first peer-reviewed papers
in this area in 2016, and multiple experimental proofs of concept for
JAK3
and
DDR1 kinases
with many other targets being pursued internally.
The company generated and released a range of molecules targeting
COVID-19 protease generated in 4 days
. Generative biology technology for the target discovery has been developed and utilized internally since 2015, and the first landmark experiment in target discovery is expected to be published in 2020.
“Insilico Medicine is a true innovator and visionary in the application of AI for novel product discovery and precision medicine. The deep generative models based on neural networks, Generative Tensorial Reinforcement Learning (GENTRL) models developed by the company generates and tests new leads with breakthrough productivity over conventional industry benchmarks.” said Amol Jadhav, PhD, Industry Analyst at Frost & Sullivan. “Frost & Sullivan is pleased to include Insilico Medicine in recognition of its pioneering research, validated full stack technology, growing pipeline of molecules, extensive portfolio and commitment toward high-profile partnerships”.
“I would like to congratulate my global teams on their tireless efforts and excellence in both AI and drug discovery that are now recognized by Frost & Sullivan. For five years we made bets on disruptive technologies with very limited resources and often struggled. But now these bets paid off and we are getting a new software suite we refer to as the Pharmaceutical Operating System to be released this year,” said Alex Zhavoronkov, PhD, co-founder and CEO of Insilico Medicine.
Insilico Medicine has been at the forefront of the competition and has established collaborations and partnerships with over 150 academic and industry partners worldwide.
###
About Frost & Sullivan
For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success.
http://www.
frost.
com
About Insilico Medicine
Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Recently, Insilico Medicine
secured $37 million in series B funding
. Since its inception, Insilico Medicine raised over $52 million, published over 80 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. Website
http://insilico.
com/
Media Contact
For further information, images or interviews, please contact:
ai@insilico.com
This part of information is sourced from https://www.eurekalert.org/pub_releases/2020-04/im-fs043020.php
